RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy.

@article{Tandon2013RBx10080307AD,
  title={RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy.},
  author={Ruchi Tandon and Vinitha Senthil and D. Nithya and Venu Pamidiboina and Ankur Kumar and Sumit D. Malik and Tridib Chaira and Manish Diwan and Praful Gupta and Raman Venkataramanan and Renu Malik and Biswajit Das and Sunanda Ghosh Dastidar and Ian Anthony Cliffe and Abhijit Ray and Pradip Kumar Bhatnagar},
  journal={European journal of pharmacology},
  year={2013},
  volume={711 1-3},
  pages={
          19-26
        }
}
Pharmacological intervention of epidermal growth factor receptor (EGFR) family members by antibodies or small molecule inhibitors has been one of the most successful approaches for anticancer therapy. However this therapy has its own limitations due to the development of resistance, over a period of time. One of the possible causes of the development of resistance to the therapy with EGFR inhibitors could be the simultaneous activation of parallel pathways. Both EGFR and insulin like growth… CONTINUE READING